MEREO BIOPHARMA (MREO)
(Delayed Data from NSDQ)
$2.81 USD
+0.03 (1.08%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $2.82 +0.01 (0.36%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.81 USD
+0.03 (1.08%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $2.82 +0.01 (0.36%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Zacks News
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
by Zacks Equity Research
Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.
Ultragenyx (RARE) Doses First Patients in Bone Disease Studies
by Zacks Equity Research
Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.
Ultragenyx (RARE) Posts Data From Osteogenesis Imperfecta Study
by Zacks Equity Research
Ultragenyx (RARE), along with partner Mereo BioPharma, announces encouraging data on mid-stage study evaluating setrusumab for patients with osteogenesis imperfecta.
What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does MEREO BIOPHARMA (MREO) have what it takes to be a top stock pick for momentum investors? Let's find out.
MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout
by Zacks Equity Research
Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.
MEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
MEREO BIOPHARMA (MREO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Ultragenyx (RARE) Begins Dosing in Pivotal Study on Setrusumab
by Zacks Equity Research
Ultragenyx (RARE) doses the first patient in a pivotal phase II/III study evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta.
Company News for Dec 21, 2020
by Zacks Equity Research
Companies in the news are: WGO, APOG, MREO, ESTE
Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate
by Zacks Equity Research
Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.
Mereo BioPharma Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Mereo BioPharma has been struggling lately, but the selling pressure may be coming to an end soon.